This is the authors' abstract. We don't add key points for this paper.
Bioavailability and bioequivalence studies play a major role in the drug development phase for both new formulations and their generic equivalents. There are various investigations to assess bioequivalence and each regulatory authority has its own guidance for the conduction of bioavailability and bioequivalence studies before approval of generic products. Bioequivalence studies are the primary needs for generic products to enter in the market. The manufacturer’s (generic product) must be in limit with that of innovator (branded) formulation (reference listed drug). This review deals with methods of bioavailability studies and requirement of bioequivalence studies necessary for filing of data for the approval of formulation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Farooq et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: